{"product_id":"recombinant-human-insulin-like-growth-factor-1-receptor-igf1r-partial-bhp10504295","title":"Recombinant Human Insulin-like growth factor 1 receptor (IGF1R), partial","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eRecombinant Human Insulin-like growth factor 1 receptor (IGF1R), partial is a recombinant protein reagent for research-use applications such as assay development, binding studies, and mechanistic experiments. It corresponds to \u003cstrong\u003eIGF1R\u003c\/strong\u003e (Homo sapiens (Human)) and is intended for RUO workflows where a defined protein standard or functional input is needed.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e E.coli (expression context can influence folding and PTMs).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression region:\u003c\/strong\u003e 763-931aa (region choice can affect activity and binding readouts).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConjugate(s)\/tag:\u003c\/strong\u003e N-terminal 6xHis-tagged (can support detection or purification depending on format).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 23.4 kDa (useful for interpreting gel migration and size-exclusion profiles).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eWhen comparing results across assays, consider that expression system and expressed region can alter glycosylation, disulfide formation, and oligomerization state, which may shift apparent potency or binding behavior in vitro.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eReceptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1\/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT\/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85KDA regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT\/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2\/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase\/signal transducer and activator of transcription pathway (JAK\/STAT). Phosphorylation of JAK proteins can lead to phosphorylation\/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK\/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5\/ASK1, which is able to directly associate with the IGF1R.When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eReagent standardization: using recombinant proteins as reference materials for quantitative calibration and cross-study comparability.\u003c\/li\u003e\n\u003cli\u003eInteraction-focused studies: mapping binding partners, affinity changes, and structure–function relationships across variants or domains.\u003c\/li\u003e\n\u003cli\u003eMulti-omic readouts: combining recombinant perturbations with transcript, protein, and functional endpoints to connect mechanism to phenotype.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eAssay development and validation: use as a defined input or standard where protein identity is required.\u003c\/li\u003e\n\u003cli\u003eBinding studies: evaluate interaction strength and specificity using plate-based or biophysical formats.\u003c\/li\u003e\n\u003cli\u003eCell-response profiling: add protein to cultured cells and interpret downstream marker changes with appropriate controls.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation is most robust when signal changes are evaluated relative to matched controls (buffer-only, unrelated protein controls, or pathway controls) and when readouts are compared across dose and time.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eIsoforms and PTMs can influence binding and activity; ensure the expressed region and expression system match your experimental needs.\u003c\/li\u003e\n\u003cli\u003eSpecies differences may affect receptor binding or antibody recognition; confirm species\/source alignment with your model.\u003c\/li\u003e\n\u003cli\u003eUse concept-level controls such as negative controls (no protein), matrix controls, or orthogonal readouts to support conclusions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProt keyword search: https:\/\/www.uniprot.org\/uniprotkb?query=IGF1R - NCBI Gene search: https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=IGF1R - PubMed search: https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=IGF1R - Ensembl search: https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=IGF1R - Reactome Pathway Browser: https:\/\/reactome.org\/content\/query?q=IGF1R --\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"1 mg","offer_id":53053050356077,"sku":"CSB-EP011087HUa0-1MG","price":1812.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53053205152109,"sku":"CSB-EP011087HUa0-100UG","price":419.0,"currency_code":"USD","in_stock":true},{"title":"20 ug","offer_id":53053205184877,"sku":"CSB-EP011087HUa0-20UG","price":224.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-EP011087HUa0-SDS.jpg?v=1772172894","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-insulin-like-growth-factor-1-receptor-igf1r-partial-bhp10504295","provider":"BioHippo","version":"1.0","type":"link"}